Matt is unworried; Kevin wants a study. I found some of the commenters on Matt's blog to be on the mark. For example, Matt writes:

Ask your local pharmaceutical company executive what he's done that competes with penicillin.

A reader replies:

ampicillin, amoxicillin, augmentin, methicillin, dicloxacillin, piperacillin, ticarcillin, cefazolin, cefipime, ceftriaxone, cefaclor, cefuroxamine, cefotetan, ceftazidime, impinem, meropenem, ertapenam....

That's funny, actually, since my own chronic asthma and bronchitis often sometimes require aggressive anti-biotics. Penicillin doesn't work for me, and I'm lucky to have a doctor who will prescribe stronger and newer drugs. But in England, under socialized medicine, my elderly parents have no choice on what anti-biotic they can get. None. Cheaper, you see? We're over-medicated over here, as the busybody left insists. Another Matt reader also targets a certain naivete about what would almost certainly happen even if we get assurances that no one wil be stopped from paying for drugs out of pocket.

We want to hear what you think about this article. Submit a letter to the editor or write to letters@theatlantic.com.